Gonadotropin signalling in epithelial ovarian cancer.
Ovarian cancer is the most lethal of all gynecologic malignancies, although its aetiology remains poorly understood. A role for the gonadotropins, follicle-stimulating hormone (FSH) and luteinising hormone (LH), has been implicated in a variety of different aspects of ovarian cancer tumorigenesis, including cellular proliferation, migration and invasion. This review focuses on the latest advances in knowledge concerning signalling pathways and functional consequences of gonadotropin action, including changes in protein-, miRNA- and gene expression, in epithelial ovarian cancer cells.
Hormones and Cancer Division, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales 2065, Australia.
Inga
I
Mertens-Walker
Robert C
RC
Baxter
Deborah J
DJ
Marsh
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006062:Gonadotropins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D007986:Luteinizing Hormone / Q000378:metabolism; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011967:Receptors, Gonadotropin / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
D018931:Antineoplastic Agents, Hormonal; D006062:Gonadotropins; D008024:Ligands; D011967:Receptors, Gonadotropin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone